Straits Times Index
3,187.66 +32.97 (+1.05%) S&P 500
5,022.21 -29.20 (-0.58%) Dow
37,753.31 -45.66 (-0.12%) Nasdaq
15,683.37 -181.88 (-1.15%) Bitcoin USD
62,263.12 -8.97 (-0.01%) CMC Crypto 200
885.54 0.00 (0.00%)
Lyell Immunopharma, Inc. (LYEL)
Pre-market:
| Previous close | 2.4100 |
| Open | 2.4000 |
| Bid | 2.3700 x 600 |
| Ask | 2.4000 x 600 |
| Day's range | 2.3500 - 2.4900 |
| 52-week range | 1.3200 - 3.9700 |
| Volume | |
| Avg. volume | 929,361 |
| Market cap | 604.748M |
| Beta (5Y monthly) | -0.56 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced that three abstracts of new nonclinical data have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024 taking place in San Diego, CA, April 5-10. One oral and two poster presentations will highlight data fro
- GlobeNewswire
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
On track to report initial clinical and translational data from lead CAR T-cell and TIL product candidates in 2024Received Orphan Drug Designation for LYL845 for the treatment of melanomaExpect to submit IND for second generation ROR1-targeted CAR T-cell product in the first half of 2024Presented nonclinical data demonstrating the ability of Lyell’s novel genetic and epigenetic reprogramming technologies to generate potent T-cell product candidates with durable cytotoxic function at multiple sci
- GlobeNewswire
Lyell Immunopharma Announces Participation in March Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced today that members of its senior management team will present and participate the following upcoming investor conferences: TD Cowen's 44th Annual Health Care Conference on Monday, March 4th at 11:10 am Eastern TimeH.C. Wainwright 2nd Annual Cell Therapy Virtual
